ReviewHead & neck oncology2009
Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.
Review in Head & neck oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.Oncoimmunology · 2020Pooled it
- Kallikrein-Related Peptidase 4 Inhibits Laryngeal Squamous Cell Carcinoma Potentially via Involvement of the Wnt/β-Catenin Signaling Pathway.Biochemical genetics · 2026Article
- Strategies to Overcome Intrinsic and Acquired Resistance to Chemoradiotherapy in Head and Neck Cancer.Cells · 2024Review
- Molecular pathways modulated by phytochemicals in head and neck cancer.Journal of cell communication and signaling · 2023Review
- Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis.Virchows Archiv : an international journal of pathology · 2022Article
- Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.Translational oncology · 2022Review
- Chorioallantoic membrane tumor models highlight the effects of cisplatin compounds in oral carcinoma treatment.iScience · 2022Article
- Impaired intratumoral natural killer cell function in head and neck carcinoma.Frontiers in immunology · 2022Article
- Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma.Frontiers in cell and developmental biology · 2022Review
- Article
- Discovery of 12O-A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor.Molecules (Basel, Switzerland) · 2020Article
- Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4.Cancer science · 2020Article
- MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma.Scientific reports · 2019Article
- Identification and characterization of dysregulated P-element induced wimpy testis-interacting RNAs in head and neck squamous cell carcinoma.Oncology letters · 2019Article
- Functional genomics screen with pooled shRNA library and gene expression profiling with extracts ofPeerJ · 2019Article
- A High-Content Screening Approach to Identify MicroRNAs Against Head and Neck Cancer Cell Survival and EMT in an Inflammatory Microenvironment.Frontiers in oncology · 2019Article
- Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression.Cancer research · 2018Article
- Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.Oncology letters · 2018Review
- Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma.Oncology letters · 2018Article
- Expression of immunohistochemical markers in non-oropharyngeal head and neck squamous cell carcinoma in Ghana.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in genomics, proteomics, bioinformatics and systems biology have unraveled the complex aberrant signaling networks in cancer. The knowledge accrued has dramatically increased the opportunities for discovery of novel molecular targets for drug development. Major emphasis is being laid on designing new therapeutic strategies targeting multiple signaling pathways for more effective disease management. However, the translation of in vitro findings to patient management often poses major challenges that limit their clinical efficacy. Here we will discuss how understanding the dysregulated signaling networks can explain the pitfalls in translating the laboratory findings from the bench-to-bedside and suggest novel approaches to overcome these problems using head and neck cancer as a prototype. The five year survival rates of HNSCC patients (about 50% at 5 years) have not improved significantly despite advancements in multimodality therapy including surgery, radiation and chemotherapy. Molecular targeted therapies with inhibitors of EGFR and VEGF either alone, or in combination with conventional treatments have shown limited improved efficacy. The key deregulated signaling pathways in head and neck squamous cell carcinoma (HNSCC) include EGFR, Ras, TGFbeta, NFkappaB, Stat, Wnt/beta-catenin and PI3-K/AKT/mTOR. The aberrant activities of these interrelated signaling pathways contribute to HNSCC development. In depth understanding of the cross-talks between these pathways and networks will form the basis of developing novel strategies for targeting multiple molecular components for more effective prevention and treatment of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.